Modig Berndt 4
4 · Axovant Gene Therapies Ltd. · Filed Apr 17, 2020
Insider Transaction Report
Form 4
Modig Berndt
Director
Transactions
- Award
Stock Option (Right to Buy)
2020-04-15+17,500→ 17,500 totalExercise: $3.45Exp: 2030-04-14→ Common Shares (17,500 underlying)
Footnotes (1)
- [F1]100% of this option will vest on April 15, 2021, subject to the Reporting Person providing continuous service to the Issuer on such date. The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested common shares. All common shares underlying the option will become fully vested upon a change in control, as that term is defined in the Issuer's 2015 Equity Incentive Plan.